country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P99406

Copy Link Print Information

Biologically Validated

Petosemtamab

(Synonyms: MCLA 158)

Kundenbewertung

Based on 1 Customer Validation

Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 2213450-26-9
Molecular Weight:145.5 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Petosemtamab Chemical Structure

CAS. Nr.: 2213450-26-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target^[2]

EGFR

0.22 nM (Kd)

LGR5

0.85 nM (Kd)

Alle EGFR Isoform-spezifische Produkte anzeigen :

In Vitro

Petosemtamab (MCLA 158) (1 µg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids
Concentration:

1 µg/mL
Incubation Time:

1, 6, 24, 72 h
Result:

Time-dependently degraded EGFR.

In Vivo

Petosemtamab (MCLA 158) (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Esophageal squamous, gastric adenocarcinoma and head & neck PDX models^[2]
Dosage:

25 mg/kg/week
Administration:

Intravenous injection (i.v.) for 6 weeks.
Result:

Inhibited tumor growth.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

8549 [NCBI] & 8549 [NCBI]

Accession

O75473 & O75473

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Immobilized EGFR Protein, Human (621a.a, CHO, His, HY-P7340) can bind Petosemtamab. The EC₅₀ for this effect is 4.45 ng/mL.
Immobilized HY-P79308 Lgr5/GPR49 Protein, Human (CHO, hFc) can bind Petosemtamab. The EC₅₀ for this effect is 85 ng/mL.

Chemical Information

CAS. Nr. 2213450-26-9
Appearance Liquid
Molecular Weight 145.5 kDa
Color Colorless to light yellow
SMILES

[Petosemtamab]
Synonyms

MCLA 158
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (260 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement): P185.

[2]. Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC). Journal of Clinical Oncology 39, no. 3_suppl

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

100 mg

Angebot einholen Auf Lager

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Biological Activity
Chemical Information
Reinheit & Dokumentation
Verweise

1/16

Human IgG1 kappa
1/16

Immobilized EGFR Protein, Human (621a.a, CHO, His, HY-P7340) can bind Petosemtamab. The EC₅₀ for this effect is 4.45 ng/mL.
1/16

Immobilized HY-P79308 Lgr5/GPR49 Protein, Human (CHO, hFc) can bind Petosemtamab. The EC₅₀ for this effect is 85 ng/mL.
1/16

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Petosemtamab

Cell-ATP Viability Detection Kit

Protein A Agarose

HOLO Human Interleukin-2 (IL-2) Detection Kit

Bradford Protein Assay Kit

PBS Buffer (1×)

DPBS Buffer (1×)

Cytotoxicity LDH Assay Kit

Antibody Inhibitor Library

Alle EGFR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Petosemtamab Related Classifications

HY-P99406 Related Classifications